培门冬酶与左旋门冬酰胺酶在儿童急性淋巴细胞白血病诱导化疗中的毒副作用和疗效分析

目的比较培门冬酶与左旋门冬酰胺酶在儿童急性淋巴细胞白血病诱导化疗中的毒副作用和临床疗效。方法将2010年10月-2012年1月我院100例儿童急性淋巴细胞白血病患者随机分成两组各50例，对照组使用培门冬酶治疗，观察组采用左旋门冬酰胺酶治疗，治疗结束后比较两组患者的毒副作用和临床疗效。结果两组完全缓解率、总有效率、不良反应情况无统计学差异（P〉0.05）；观察组用药次数和住院时间明显多于对照组，差异有统计学意义（P〈0.05）。结论培门冬酶与左旋门冬酰胺酶诱导化疗儿童急性淋巴细胞白血病均有较好疗效，但培门冬酶用药次数和住院时间明显缩短，需在临床应用时加以注意。

The side effects and clinical efficacy of Pegaspargase and L-asparaginase in the treatment of childhood acute lymphoblastic leukemia

Objective To compare The side effects and clinical efficacy of Pegaspargase and L-asparaginase in the treatment of childhood acute lymphoblastic leukemia, and provide a reference for the clinical treatment of children with acute lymphoblastic leukemia. Methods During October 2010-2012 in January during our hospital, 100 cases of childhood acute lymphoblastic leukemia patients were randomly divided into control group and observation group, 50 cases in each group of patients, the control group patients were treated with pegaspargase, and the observation group were treated with L-asparaginase, after treatment, to compare the clinical efficacy and side effects. Results The differences in the complete remission rate, the total effective rate, and the adverse reactions of two groups of patients were no significant（P〉0.05）. The number of drugs and hospitalization time of the observation group of patients were significantly more than the control group of patients, the differences of two groups of patients were statistically significant（P〈0.05）. Conclusion In children with acute lymphoblastic leukemia induction chemotherapy, pegaspargase and L-asparaginase has better clinical efficacy and incidence of adverse reactions undifferentiated, but the number of patients treated with pegaspargase medication and hospitalization time was significantly shorter.